Longitudinal Evaluation of Silicone Hydrogel (LASH) Study (LASH)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00727402 |
|
Recruitment Status :
Completed
First Posted : August 4, 2008
Results First Posted : February 10, 2011
Last Update Posted : February 15, 2012
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease |
|---|
| Corneal Infiltrates |
| Study Type : | Observational |
| Actual Enrollment : | 205 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | The Longitudinal Evaluation of Silicone Hydrogel (LASH) Contact Lens Study |
| Study Start Date : | October 2006 |
| Actual Primary Completion Date : | January 2009 |
| Actual Study Completion Date : | October 2009 |
| Group/Cohort |
|---|
|
Observational
healthy patients fit into lotrafilcon A contact lenses for continuous wear
|
- Cumulative Incidence of Corneal Inflammatory Events [ Time Frame: annual ]Unadjusted cumulative incidence of corneal inflammatory events (CIE)using survival analysis methods. CIE are corneal infiltrates found in an otherwise clear cornea.
Biospecimen Retention: Samples Without DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 15 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- The patient must be at least 15 years old. Children younger than this may not be mature enough for CW, and may have difficulty following the strict instructions required for CW or sitting through the exam procedures.
- The patient must have clear central corneas and free of any anterior segment disorders.
- The patient must have a spectacle corrected spherical refractive error between +5.50 D and -11.00 D with less than or equal to 1.00 D refractive cylinder. The parameters of the Ciba Vision Night and Day Lenses range from +6.00 to -10.00 D, and can correct the refractive range of this population. Monovision correction will be allowed only if the near eye does not exceed +6.00 D.
- The patient must be correctable to 20/25 or better with spectacles. Amblyopia will be excluded.
- Flat and steep corneal curvatures from SimK readings must be between 39.00 and 48.00 D. Corneal curvatures outside this range may be indicative of a disease state, and patients are not expected to comfortably wear either the 8.4 mm or 8.6 mm base curve available in Night and Day.(Dumbleton K 2002)
- Can be successfully fit with lotrafilcon A lenses at the enrollment visit.
Exclusion Criteria:
- The patient has worn rigid gas permeable lenses within the last 30 days or PMMA lenses within the last 3 months. These lenses can transiently alter the corneal shape and influence the fitting of soft lenses.
- The patient must not be a current extended wear user of lotrafilcon A lenses.
- The patient has an autoimmune disease (except for Hashimoto's Thyroiditis), immunocompromising disease, connective tissue disease, atopic dermatitis, insulin dependent diabetes, or any other systemic disease that in the investigator's opinion will affect ocular health.
- The patient is taking chronic systemic medications such as corticosteroids, antimetabolites, or non-steroidal anti-inflammatory agents or any other medication that in the investigator's opinion will affect ocular physiology.
- The patient has any ocular disease or condition such as aphakia, corneal dystrophies, corneal edema, external ocular infection, iritis, or had any anterior segment surgery.
- The patient is taking any ocular medications.
- The patient must have less than or equal to grade 2 on any of the slit lamp observations of: upper tarsal papilla, corneal staining, corneal neovascularization, conjunctival injection, and lid erythema or scales. Slit lamp findings higher than grade 2 bias the patient toward an adverse event and it may be difficult to detect true change related to CW.
- The patient is pregnant.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00727402
| United States, Ohio | |
| University Hospitals Case Medical Center | |
| Cleveland, Ohio, United States, 44106 | |
| Principal Investigator: | Loretta B Szczotka-Flynn, OD, MS | Case Western Reserve University |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Loretta Szczotka-Flynn, Professor, Case Western Reserve University |
| ClinicalTrials.gov Identifier: | NCT00727402 |
| Other Study ID Numbers: |
K23EY015270-01 ( U.S. NIH Grant/Contract ) |
| First Posted: | August 4, 2008 Key Record Dates |
| Results First Posted: | February 10, 2011 |
| Last Update Posted: | February 15, 2012 |
| Last Verified: | February 2012 |

